Guided Poster Tour


GUIDED POSTER TOUR 1 - Liffey Hall 1 Monday, June 18, 2012 12:45 - 14:15

Basic Science

1473

The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein

T. Hasegawa, M. Konno, T. Baba, N. Sugeno, A. Kikuchi, E. Miura, A. Takeda (Sendai, Japan)

1455

GDNF replacement augments motor impairments and nigrostriatal dopamine deficits in 12 month old mice with a partial deletion of GDNF

H.A. Boger, G.A. Gerhardt, A. C. Granholm, O.M. Littrell (Charleston, SC, USA)

1468

Characterization of adult neurogenesis in a transgenic mouse model of multiple system atrophy

P. Fuchs, L. Aigner, W. Poewe, G.K. Wenning, N. Stefanova (Innsbruck, Austria)

1469

ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome

A. Grünewald, B. Arns, P. Seibler, A. Rakovic, A. Münchau, A. Ramirez, C.M. Sue, C. Klein (Lübeck, Germany)

1478

A rodent model for direct visualization of α-synuclein oligomers in the nigrostriatal system

L.V. Kalia, H. Dimant, S.K. Kalia, L.N. Kibuuka, D. Ebrahimi-Fakhari, N.R. McFarland, P.J. McLean (Toronto, ON, Canada)

1447

Inflammatory responses are attenuated in incidental Lewy body disease

R.S. Akhtar, J.M. Milber, J.V. Noorigian, L.R. White, H. Petrovitch, G.W. Ross, J.E. Duda (Philadelphia, PA, USA)

1476

Mild dopaminergic lesions are accompanied by robust changes in subthalamic nucleus activity

M.L.F. Janssen, D.G.M. Zwartjes, S.K.H. Tan, R. Vlamings, A. Jahanshahi, T. Heida, G. Hoogland, H.W.M. Steinbusch, V. Visser-Vandewalle, Y. Temel (Maastricht, Netherlands)

1480

Enteric and central nervous system pathology in a novel mouse model: Implications for pathogenesis in pre-motor Parkinson's disease

L.P. Kelly, P.M. Carvey, R.A.E. Bakay, J.H. Kordower (Chicago, IL, USA)

1521

Implication of autophagy in Parkinson's disease: Rotenone-based models

N. Xiong, M. Jia, J. Xiong, J. Huang, T. Wang (Wuhan, China)

GUIDED POSTER TOUR 2 - Liffey Hall 2 Monday, June 18, 2012 12:45 - 14:15

Lewy Body Dementia and other dementias in movement disorders

211

Withdrawn by Author

 

206

Cerebral vasculitis mimicking frontotemporal dementia

A. Mc Carthy, E. Mulroy, K. O'Rourke, T. Lynch (Dublin, Ireland)

37

Comparison of The Movement Disorder Society criteria for Parkinson's disease dementia with routine clinical neuropsychological testing

B.R. Barton, B. Bernard, G.T. Stebbins, J. Goldman, B. Dubois, C.G. Goetz (Chicago, IL, USA)

73

Parkinson's disease patients fulfilling level-I criteria for dementia differ in ADL functions and phenotype

I. Liepelt-Scarfone, D. Prakash, J.B.M. Christ, E. Riedl, I. Csoti, M. Fruhmann Berger, S. Graeber, D. Berg (Tuebingen, Germany)

207

The evolutionarily conserved function of HtrA2 in mice prevents neurodegeneration by oligomeric α-synuclein

M.M. Rahman, M. L. Liu, S. Akhter, H.J. Kim, S.T. Hong (Jeonju, Korea)

203

Safety, tolerability, and efficacy of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies

B. Boeve, K. Kuntz, D. Drubach, L. Allen, D. Drubach (Rochester, MN, USA)

209

Neuropsychological differences in mild cognitive impairment (MCI) with symptoms of Lewy body disease (LBD)/Parkinson's disease (PD) and other MCI causes

M.J. García Basalo, D.J. Bauso, J.P. Tartari, C.V. Stefani, N. Cámpora, M. Fernández, J.I. Rojas, E. Cristiano, A. Golimstok (Buenos Aires, Argentina)

204

Pathological accumulation of α-synuclein and Aβ in Parkinson's disease with dementia

M.C. Campbell, P.T. Kotzbauer, N.J. Cairns, B.A. Racette, S.D. Tabbal, J.S. Perlmutter (St. Louis, MO, USA)

44

Elevated homocysteine levels predict cognitive dysfunction in an incident cohort of non-demented Parkinson's disease patients

G.W. Duncan, T.K. Khoo, A.J. Yarnall, J.T. O'Brien, D.J. Brooks, R.A. Barker, D.J. Burn (Newcastle upon Tyne, United Kingdom)

113

Cognitive symptoms in a population-based cohort to study parkinsonism

E. J. Vollstedt, J. Graf, A. Lorwin, J. Hagenah, V. Tadic, N. Brüggemann, A. Schmidt, S. Tunc, J. Hampf, L. Piskol, C. Klein, M. Kasten (Lübeck, Germany)

GUIDED POSTER TOUR 3 - Wicklow Hall 1 Monday, June 18, 2012 12:45 - 14:15

Parkinson's disease: Cognition

95

Correlation of cognitive impairment evaluated by Montreal Cognitive Assessment with functional brain imaging of Parkinson's disease patients

K. Ohta, T. Osada, T. Tajima, M. Seki, Y. Shinohara (Tokyo, Japan)

76

Visual sampling during walking in people with Parkinson's disease and the influence of task complexity

S. Lord, B. Galna, D. Daud, N. Archibald, D. Burn, L. Rochester (Newcastle upon Tyne, United Kingdom)

109

Severe olfactory dysfunction is predictive of dementia associated with Parkinson's disease: A 3-year longitudinal study

T. Baba, A. Kikuchi, K. Hirayama, Y. Nishio, Y. Hosokai, S. Kanno, T. Hasegawa, N. Sugeno, M. Konno, E. Miura, E. Mori, A. Takeda (Sendai, Japan)

110

A novel test for assessing gait under multiple-task conditions: Comparison of the performance among adults, elderly and patients with Parkinson's disease

E. Tardeli, N. Santo, R. Bovi, D. Bertolo, M.E.P. Piemonte (Sao Paulo, Brazil)

75

Olfactory dysfunction correlation to non-motor symptoms in Parkinson's disease patients

G.J. Lopez, K. Bayulkem, B. McElroy, M. Brooks, B. Bayulkem, M. Hallett (Bethesda, MD, USA)

83

GBA mutation carriers with Parkinson's disease are not at increased risk for cognitive impairment

I. Mata, J. Leverenz, J. Trojanowski, A. Chen-Plotkin, B. Ritz, S. Rhodes, S. Factor, C. Wood-Siverio, J. Quinn, K. Chung, A. Espay, F. Revilla, K. Edwards, T. Montine, C. Zabetian (Seattle, WA, USA)

106

Association between olfactory dysfunction and cognition in the PPMI study

A. Siderowf, J.F. Morley, J.E. Duda, D. Weintraub, For the PPMI Investigators (Philadelphia, PA, USA)

41

Motor impulsivity in Parkinson's disease subtypes: Postural instability with gait difficulty versus tremor predominant

D.O. Claassen, S.A. Wylie (Nashville, TN, USA)

116

Dual task effects during sentence production in Parkinson's disease

J.P. Wilson, L.J.P. Altmann, A.A. Hazamy, E. Stegemöller, M.S. Okun, C.J. Hass (Gainesville, FL, USA)

88

Baseline data of the DeNoPa-Kassel cohort: Biomarkers and non-motor features of 160 drug naïve PD subjects and 115 matched healthy controls

B. Mollenhauer, E. Trautmann, T. Wicke, J. Ebentheuer, F. Sixel-Döring, C. Trenkwalder, DeNoPa Study Group (Kassel, Germany)

GUIDED POSTER TOUR 4 - Wicklow Hall 2 Monday, June 18, 2012 12:45 - 14:15

Sleep disorders and RLS

688

Restless legs syndrome in Korean patients with drug-naïve Parkinson's disease: A nation-wide study

J. Youn, H.Y. Shin, W.T. Yoon, J.S. Kim, H. Shin, J.Y. Ahn, J.W. Cho (Seoul, Korea)

676

Quantifying daytime sleepiness in Parkinson's disease

K. Kotschet, W. Johnson, R. Griffiths, M. Horne (Fitzroy, Australia)

683

How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behavior disorder

R.B. Postuma, A.E. Lang, J.F. Gagnon, A. Pelletier, J. Montplaisir (Montreal, QC, Canada)

1228

Restless legs syndrome outside the blood-brain barrier – Evidence from domperidone

S. Rios Romenets, Y. Dauvilliers, V. Cochen De Cock, B. Carlander, S. Bayard, C. Galatas, C. Wolfson, R. Postuma (Montreal, QC, Canada)

673

Sleep and circadian rhythm disruption in incident Parkinson's disease – A multimodal analysis

D.P. Breen, R. Vuono, K. Fisher, S. Nawarathna, J.M. Shneerson, A.B. Reddy, R.A. Barker (Cambridge, United Kingdom)

687

REM sleep without atonia and freezing of gait in Parkinson's disease

A. Videnovic, C.C. Marlin, J. Planetta, L. Alibiglou, D.E. Villancourt, C.D. MacKinnon (Chicago, IL, USA)

674

Effects of dopaminergic medications on objective and subjective sleep in Parkinson's disease

L.M. Chahine, J. Daley, S. Horn, A. Colcher, H. Hurtig, C. Cantor, N. Dahodwala (Philadelphia, PA, USA)

1227

A rare variant near a potassium channel-related gene in familial restless legs syndrome

I. Pichler, C. Schwienbacher, A. Zanon, C. Fuchsberger, A. Serafin, F. Marroni, M.F. Facheris, C. Tellgren-Roth, U. Gyllensten, J.F. Gusella, A.A. Hicks, P.P. Pramstaller (Bolzano, Italy)

1215

Comparison of pregabalin, pramipexole and placebo effects on symptoms, limb movements and sleep maintenance in restless legs syndrome (Willis-Ekbom disease)

R.P. Allen, P.M. Becker, J. Patrick, S. Dubrava, D. Garcia-Borreguero, A. Lankford, C. Chen, L. Knapp, J. Miceli (Baltimore, MD, USA)

684

Sleep disturbances and dysautonomic dysfunction are associated in patients with Parkinson's disease

S. Realmuto, V. Arnao, A. Cinturino, F. Valentino, G. Famoso, V. Perini, S. Mastrilli, P. Aridon, P. Ragonese, G. Savettieri, M. D'Amelio (Palermo, Italy)

GUIDED POSTER TOUR 5 - Liffey Hall 1 Tuesday, June 19, 2012 12:15 - 13:45

Parkinson's disease: Clinical trials

409

Bilateral STN stimulation reduces the occurrence of freezing of gait in Parkinson's disease

H. Devos, G. Vervoort, L. Münks, W. Vandenberghe, B. Nuttin, A. Nieuwboer (Leuven, Belgium)

366

Fox Trial Finder (FTF): Online clinical trial matching to connect subjects with Parkinson's trials

M. Frasier, S. Chowdhury, C.C. Meunier, D. Brooks (New York, NY, USA)

349

Continuous subcutaneous carbidopa improves levodopa pharmacokinetics in Parkinson's disease patients

Y. Caraco, N. Giladi, S. Oren, P.A. LeWitt (Jerusalem, Israel)

346

A phase III clinical trial of coenzyme Q10 (QE3) in early Parkinson's disease: Parkinson Study Group QE3 Investigators

M.F. Beal (New York, NY, USA)

408

Accordion pill carbidopa/levodopa for improved treatment of advanced Parkinson's disease symptoms

P.A. LeWitt, H. Friedman, N. Giladi, T. Gurevich, H. Shabtai, R. Djaldetti, N. Roizen, S. Hassin-Baer, O. Cohen, G. Yahalom, I. Schlesinger, M. Nassar, R. Milo, N. Navon (Jerusalem, Israel)

433

Strength training outcomes for airway protection in PD

C.M. Sapienza, M. Troche, E.P. Silverman, J. Rosenbek, N. Musson (Gainesville, FL, USA)

419

Gait improvement in patients with Parkinson's disease after training in real and virtual enviroment

J.E. Pompeu, F.A. Mendes, K.G. Silva, T.P. Oliveira, A.M. Lobo, S.M.A.A. Pompeu, A.P. Zomignani, M.E.P. Piemonte (São Paulo, Brazil)

430

Dopamine agonists and dyskinesia in advanced Parkinson's disease: A network meta-analysis of rotigotine, pramipexole and ropinirole as adjunct therapy to levodopa

E. Senior, P. Dedeken, H. Naci (Brussels, Belgium)

411

Randomized, double-blind, double-dummy study of continuous infusion of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: Efficacy and safety

C.W. Olanow, A. Antonini, K. Kieburtz, H.H. Fernandez, A.J. Espay, D.G. Standaert, A.D. Vanagunas, K.L. Widnell, S. Freeman, W.Z. Robieson, Y. Pritchett, K. Chatamra, J. Benesh, R.A. Lenz (New York, NY, USA)

385

Randomized, phase 3, double-blind, double-dummy study of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: Functional and quality-of-life outcomes

K. Kieburtz, A. Antonini, C.W. Olanow, H.H. Fernandez, A.J. Espay, D.G. Standaert, S. Hass, K.L. Widnell, W.Z. Robieson, Y. Pritchett, K. Chatamra, J. Benesh (Rochester, NY, USA)

GUIDED POSTER TOUR 6 - Liffey Hall 2 Tuesday, June 19, 2012 12:15 - 13:45

Surgical Therapy: Parkinson's disease

533

Effects of subthalamic nucleus lesions and stimulation upon corticostriatalafferents in the 6-hydroxydopamine-lesioned rat

R.H. Walker, C. Moore, G. Davies, L. Dirling, R.J. Kock, C.K. Meshul (Bronx, NY, USA)

534

Evaluation of electrode design on activation volumes produced during deep brain stimulation

S.N. Washburn, C.R. Butson (Plano, TX, USA)

536

Parkinson's Study Group Neurosurgical Working Group (PSG-NSWG) deep brain stimulation (DBS) non-motor symptoms (NMS) survey: Real-world preoperative practice patterns

M.K. York, L. Marsh, J. Jimenez-Shahed, M.S. Okun, E. Moro, R. Kumar (Houston, TX, USA)

470

Deep brain stimulation and decision making in apathetic patients: A PET study

F. Antonelli, A.P. Strafella, Y.Y. Poon, A.M. Lozano, M. Hodaje, G. Pellecchia, F. Valzania, J.H. Ko, A. Lang, S. Houle, E. Moro (Toronto, ON, Canada)

462

Comprehensive, multi-disciplinary DBS screening for Parkinson's patients: No room for “short cuts”

H. Abboud, A. Machado, M. Deogaonkar, A. Ahmed, M. Gostkowski, S. Cooper, I. Itin, P. Sweeney, M. Pandya, C. Kubu, D. Floden, P. Ford, H. Fernandez (Cleveland, OH, USA)

521

Is age a predictor for length of hospital stay in deep brain stimulation?

E.M. Presant, Y. Song, P. Konrad, J. Neimat, F. Phibbs (Nashville, TN, USA)

484

Saccadic eye movement abnormalities in Parkinson's disease treated by levodopa and deep brain stimulation

M. Dec, M. Rudzinska, M. Tutaj, A. Szczudlik (Kraków, Poland)

522

The dominant subthalamic nucleus: A gait analysis study

M.G. Rizzone, I. Carpinella, C.A. Artusi, M. Lanotte, L. Lopiano, A. Marchisio, A. Merola, M. Rabuffetti, D.V. Roccatagliata, M. Zibetti, M. Ferrarin (Torino, Italy)

515

Randomized multicenter trial comparing bilateral subthalamic nucleus DBS and bilateral globus pallidus internus DBS for advanced Parkinson's disease (NSTAPS)

V.J. Odekerken, T. van Laar, A. Mosch, J. van Vugt, P.C. Nijssen, B.A. Schmand, P.R. Schuurman, R.M. de Bie (Amsterdam, Netherlands)

524

Stereotactic neurosurgery for movement disorders in a world perspective. Results from the WSSFN-supported survey

V. Jourdain, G. Schechtmann (Stockholm, Sweden)

GUIDED POSTER TOUR 7 - Wicklow Hall 1 Tuesday, June 19, 2012 12:15 - 13:45

Rating scales and assessment tools

332

Patient-centeredness in Parkinson's disease care: Development and validation of a patient experience questionnaire

M. van der Eijk, M.J. Faber, J.W.M. Aarts, M. Munneke, B.R. Bloem (Nijmegen, Netherlands)

291

How slow is too slow? Objective measurement of bradykinesia in Parkinson's disease using novel non-invasive devices

J.E. Alty, S. Jamieson, M.A. Lones, S.L. Smith (Leeds, United Kingdom)

329

Calibration of the UPDRS to the MDS-UPDRS

G.T. Stebbins, C.G. Goetz, B.C. Tilley (Chicago, IL, USA)

326

How should pushing off or the use of assistive devices be incorporated in the timed Up and Go (TUG)?

P.N. Schmidt, J.G. Nutt, M. Guttman, A.D. Siderowf, E.C. Nelson, J. Zamudio, M.S. Okun (Miami, FL, USA)

330

The association between NT-proCNP, functional capacity and clinical stage in patients with Parkinson's disease

D. Koziorowski, R. Tomasiuk, S. Szlufik, A. Friedman (Warsaw, Poland)

334

Determining minimal clinically important difference for health-related quality of life scales in Parkinson's disease

Y. Winter, D. Lubbe, W.H. Oertel, R. Dodel (Marburg, Germany)

305

Freezing of gait in Parkinson's disease: Associations with disease severity, falls, quality of life and clinical balance measures

R.A. Gruber, L.R.S. Almeida, J.H. Goldstein Elman, N.N. Negreiros, G.T. Valenca (Toronto, ON, Canada)

322

Metric evaluation of a novel scale to assess psychosis in patients with Parkinson's disease

W.G. Ondo, H. Peng (Houston, TX, USA)

308

Quantifying freezing of gait in Parkinson's disease during the instrumented timed Up and Go test

F.B. Horak, M. Mancini, R. Cohen, J.J. Nutt (Portland, OR, USA)

304

MDS-UPDRS non-English translation program

C.G. Goetz, G.T. Stebbins, N. LaPelle, J. Huang, B.C. Tilley (Chicago, IL, USA)

GUIDED POSTER TOUR 8 - Wicklow Hall 2 Tuesday, June 19, 2012 12:15 - 13:45

Parkinson's disease: Neuropharmacology

134

Determination of plasma, brain and cerebrospinal fluid levels of L-DOPA in the MPTP-lesioned cynomolgus macaque model of Parkinson's disease

P. Huot, T.H. Johnston, J.B. Koprich, S.H. Fox, J.M. Brotchie (Toronto, ON, Canada)

138

Medication reminder service for mobile phones; an open usability study in patients with Parkinson's disease

T. Keränen, S. Liikkanen (Kuopio, Finland)

140

Maintenance of constant steady state therapeutic plasma concentrations of levodopa following its continuous subcutaneous administration with carbidopa

O. Yacoby-Zeevi, P.A. LeWitt (West Bloomfield, MI, USA)

163

Adherence to once-daily dopamine agonists in levodopa-treated Parkinson's disease patients is related to first dopamine replacement therapy

D. Santos-García, M. Prieto-Formoso, R. de la Fuente- Fernández (Ferrol, Spain)

161

European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD

A. Rizos, P. Martinez-Martin, A. Martin, T. Henriksen, B. Kessel, I. Koch, G. Durner, A. Antonini, P. Odin, C. Falup-Pecurariu, P. Reddy, S. Robinson, M. Silverdale, G. MacPhee, A. Douiri, S. Lindvall, K. Ray Chaudhuri (London, United Kingdom)

130

Human microdyalisis during acute high frequency stimulation of internus globus pallidus increases dopamine release and improves parkinsonian symptoms

R.R.C. Martinez, M.C. Carvalho, M.L. Brandão, M.J. Teixeira, J. Navarro, E.T. Fonoff (São Paulo, Brazil)

160

A multicentre European comparative survey of motor and non motor effects of subcutaneous apomorphine infusion and intrajejunal levodopa infusion in Parkinson's disease

P. Reddy, P. Martinez-Martin, A. Antonini, D. Calandrella, M. Pilleri, P. Odin, A. Martin, T. Henriksen, A. Rizos, R. Katzenschlager, N. Bryndum, A. Glad, L. Timmermann, H. Salimi Dafsari, G. Ebersbach, M.G. Kramberger, M. Trost, Z. Pirtosek, K. Wenzel, V. Tomantschger, A. Storch, H. Reichmann, A. Ceballos-Baumann, K.R. Chaudhuri (London, United Kingdom)

150

Parkinson's disease responding to smoking

A. Mc Carthy, K. O'Rourke, T. Lynch (Dublin, Ireland)

146

Peripheral neuropathy during continuous levodopa duodenal infusion: Outcome of 15 patients

F. Mancini, C. Comi, D. Calandrella, M. Lacerenza, G. Riboldazzi, C. Pacchetti, M. Coletti Moia, L. Manfredi, A. Antonini (Milan, Italy)

135

L-745,870 reduces L-DOPA-induced dyskinesia in the MPTP-lesioned primate at doses at which it is a selective antagonist at D4 dopamine receptors

P. Huot, T.H. Johnston, J.B. Koprich, S.H. Fox, J.M. Brotchie (Toronto, ON, Canada)

GUIDED POSTER TOUR 9 - Liffey Hall 1 Wednesday, June 20, 2012 12:00 - 13:30

Genetics

1402

CAG analysis, haplotypes, unstable repeats, recombination, pedigrees, gene dosage, genotype-phenotype relationship and genetics polymorphisms in the SCA2 (ATXN2) locus

J.M. Laffita-Mesa, L.C. Velázquez-Pérez, Y. Vázquez Mojena, V. Kourí, A. Martínez, A. Miranda, L. Peña Serrano, D.A. Cuello Almarales, R. Aguilera Rodriguez, V. Berovides (Holguin, Cuba)

1407

PRRT2 mutations are a major cause of paroxysmal kinesigenic dyskinesia in the European population

A. Méneret, D. Grabli, C. Depienne, C. Gaudebout, F. Picard, A. Dürr, I. Lagroua, D. Bouteiller, M. Vidailhet, A. Brice, E. Roze (Paris, France)

1398

High COMT activity is associated with earlier age at onset in PD

S. Klebe, J.L. Golmard, R. Charfi, G. Kuhlenbäumer, C. Klein, J. Hagenah, T. Gasser, I. Wurster, S. Lesage, D. Lorenz, G. Deuschl, M. Saad, M. Martinez, F. Durif, P. Pollak, P. Damier, F. Tison, A. Dürr, P. Amouyel, J.C. Lambert, C. Tzourio, C. Maubaret, F. Charbonnier-Beaupel, K. Tahiri, M. Vidailhet, A. Brice, J.C. Corvol (Paris, France)

1417

Is the brain-derived neurotrophic factor (BDNF) Val66Met genetic polymorphism associated with impulsive-compulsive behaviours in Parkinson's disease?

S.S. O'Sullivan, P. Cheshire, A. Djamshidian, K. Bertram, D.R. Williams, A.J. Lees, T. Foltynie (Cork, Ireland)

1425

First genome-wide association study in multiple system atrophy

A. Sailer, on behalf of the MSA GWAS Consortium (London, United Kingdom)

1422

PINK1-dependent mitophagy in dopaminergic neurons does not require LC3 conversion

A. Rakovic, K. Shurkewitsch, P. Seibler, D. Krainc, C. Klein (Lübeck, Germany)

1377

A clinicopathological study of parkin-linked parkinsonism – A study of 5 cases and comparison with Parkinson's disease

K.M Doherty, L. Silveira-Moriyama, L. Parkkinen, D. Healy, M. Farrell, N.E. Mencacci, Z. Ahmed, F. Brett, J. Hardy, N. Quinn, T.T. Counihan, T. Lynch, T. Revesz, A.J. Lees, J.L. Holton (London, United Kingdom)

1418

Contiguous gene deletions involving the SGCE gene: A clinical description

K.J. Peall, A.J. Waite, M.A. Kurian, M. Smith, H. Pall, T. Nestor, M.D. King, D.J. Blake, M.J. Owen, H.R. Morris (Cardiff, United Kingdom)

1363

Prrt2 gene mutations: From paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine

A. Gardiner, K.P. Bhatia, M. Stameou, R.C. Dale, M. Kurian, S. Schneider, G.M. Wali, T. Counihan, S. Spacey, E.M. Valente, L. Silveira-Moriyama, H.A. Taive, S. Raskin, J.W. Sander, A. Lees, T. Warner, D. Kullman, N.W. Wood, M. Hanna, H. Houlden (London, United Kingdom)

1360

Alpha-synuclein H50Q, a novel pathogenic mutation for Parkinson's disease

S. Appel-Cresswell, C. Vilarino-Guell, I. Yu, B. Shah, D. Weir, C. Thompson, J.A. Stoessl, M.J. Farrer (Vancouver, BC, Canada)

GUIDED POSTER TOUR 10 - Liffey Hall 2 Wednesday, June 20, 2012 12:00 - 13:30

Parkinson's disease: Phenomenology

1586

Abnormalities of voice quality in the course of disease progression in Parkinson's disease

W. Grönheit, U. Schlegel, S. Skodda (Bochum, Germany)

1570

An observational study of the impact of early versus delayed treatment on quality of life in Parkinson's disease

D.J.M. McGhee, R. Caslake, C.E. Harris, C.E. Counsell (Aberdeen, United Kingdom)

1551

Asymmetry of gait in parkinsonian patients and its role in the development of freezing

G. Frazzitta, G. Pezzoli, G. Bertotti, G. Riboldazzi, R. Rovescala, R. Maestri (Montescano, Italy)

1580

Baseline findings and Parkinson's disease prognosis

A.H. Rajput, M.L. Rajput, A.H. Rajput (Saskatoon, SK, Canada)

1533

Progressive cortical degeneration in Parkinson's disease

D. Benninger, J. Dukart, J. von Meyenburg, S. Thees, C. Bassetti, D. Waldvogel, S. Kollias, K. Iseki, B. Draganski (Lausanne, Switzerland)

1568

Unexplained lower limb pain syndrome in Parkinson's disease: A variant of central pain

A. Martin, S. Robinson, M. Parry, A.H.V. Schapira, A. Rizos, C. Clough, K. Ray Chaudhuri (London, United Kingdom)

1596

The CamPaIGN study of incident Parkinson's disease: Natural history over the first 10 years

C.H. Williams-Gray, S.L. Mason, J.R. Evans, T. Foltynie, R.A. Barker (Cambridge, United Kingdom)

1588

Cognitive correlates of freezing phenomenon in Parkinson's disease

E. Stefanova, M. Jecmenica Lukic, F. Agosta, V. Spica, M. Filippi, V. Kostic (Belgrade, Serbia)

1565

Patterns of daily ambulatory activity are different in early Parkinson's disease compared with controls

S. Lord, A. Godfrey, B. Galna, D. Burn, L. Rochester (Newcastle upon Tyne, United Kingdom)

1543

Freezing of gait in Parkinson's disease under virtual reality conditions studied with a novel treadmill system: A pilot trial

K. Czarnecki, K. Iseki, C.R. Collins, P.T. Ghosh, H.S. Park, J.W. Yoon, M. Hallett (Bethesda, MD, USA)

GUIDED POSTER TOUR 11 - Wicklow Hall 1 Wednesday, June 20, 2012 12:00 - 13:30

Huntington's disease

191

Frontal subcortical dysfunction underlying the applause sign: A study in Huntington's disease subjects

S. Nageshwaran, Y. Bordelon, S. Perlman (London, United Kingdom)

199

Molecular analysis of Huntington's disease in a Cuban population

Y. Vázquez-Mojena, J.M. Laffita-Mesa, L. Laguna-Salvia, Y. González-Zaldívar, D. Almaguer-Gotay, P. Zayas-Feria, L.E. Almaguer-Mederos, R. Rodríguez-Labrada, L. Velázquez-Pérez (Holguin, Cuba)

168

A proposal for a physiotherapy programme to improve gait, balance and functional independence in Huntington's disease

T. Capato, M. Haddad, M.E. Piemonte, E.R. Barbosa (Sao Paulo, Brazil)

200

Antisense oligonucleotides as molecular tools to silence prolonged (CAG)n tracts in Huntington's disease

R. Vlamings, M.M. Evers, W.M.C. van Roon-Mom, S.A.M. Mulders, M.L.F. Janssen, R.C. Verheul, J.C.T. van Deutekom, Y. Temel (Maastricht, Netherlands)

180

Bilateral globus pallidus deep brain stimulation for Huntington's disease: Long term outcome of chorea

V. Gonzalez, L. Cif, B. Biolsi, M. Zanca, E. Sanrey, A.M. Moura, T. Roujeau, S. James, P. Coubes (Montpellier, France)

185

Baseline characteristics of the PREQUEL cohort: An interventional trial in pre-manifest Huntington's disease

A. Killoran, K.M. Biglan, E. Julian-Baros, N. Yoritomo, C.A. Ross (Rochester, NY, USA)

195

Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease

V. Shen, K. Clarence-Smith, C. Hunter, J. Jankovic (Deerfield, IL, USA)

197

Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease

V. Shen, K. Clarence-Smith, C. Hunter, J. Jankovic (Deerfield, IL, USA)

181

Cognitive decline in Huntington's disease is associated with CAG repeat length

A. Hellman, B. Durbin-Johnson, X.R. Chen, D. Harvey, C. Decarli, T. Tempkin, V. Wheelock (Philadelphia, PA, USA)

182

Neuropathology of McLeod neuroacanthocytosis syndrome

H.H. Jung, F. Geser, J. Haybäck, B. Bader, A. Danek, P. Fuhr, M. Neumann, R. Reichard, B. Udd, A. Zeman, M. Tolnay (Zürich, Switzerland)

GUIDED POSTER TOUR 12 - Wicklow Hall 2 Wednesday, June 20, 2012 12:00 - 13:30

Parkinson's disease: Behavorial disorders

832

The neural correlates of visual misperceptions in Parkinson's disease: Disorder of attentional networks

J.M. Shine, G.M. Halliday, S.J. Bolitho, S.L. Naismith, S.J.G. Lewis (Sydney, Australia)

799

Creative thinking in patients with Parkinson's disease and healthy subjects: The artistic profession makes the difference?

M. Canesi, M.L. Rusconi, E. Reali, F. Moroni, R. Cilia, G. Pezzoli (Milan, Italy)

806

Decision-making, impulsivity and behavioural addictions: Do Parkinson's patients jump to conclusions?

A. Djamshidian, S.S. O'Sullivan, Y. Sanotsky, S. Sharman, Y. Matviyenko, T. Foltynie, R. Michalczuk, I. Aviles-Olmos, K. Doherty, M. Selikhova, H. Bowden-Jones, E. Joyce, A.J. Lees, B.B. Averbeck (London, United Kingdom)

849

Towards the detection of the neural correlates of Parkinson's disease sub-types using MRI

K. Rosenberg Katz, T. Herman, Y. Jacob, G. Nir, J.M. Hausdorff (Tel Aviv, Israel)

817

Rotigotine transdermal patch improved neuropsychiatric features (apathy, anhedonia, anxiety, and depression) and fatigue in patients with Parkinson's disease: Post-hoc analysis of five double-blind placebo-controlled studies

R.A. Hauser, P.A. Nausieda, E. Surmann, K. Moran, P. Barone (Tampa, FL, USA)

865

Morphologic changes of dendritic spines of intratelencephalic-type neurons in the motor cortex of a rat model of levodopa-induced dyskinesia

T. Ueno, H. Nishijima, A. Arai, K. Migita, J. Yamada, M. Baba, S. Ueno, M. Tomiyama (Aomori, Japan)

828

Effects of bilateral subthalamic nucleus deep brain stimulation on impulse control and repetitive behavior disorders in Parkinson's disease: Results from 89 patients

Y.E. Kim, H. Kim, H.J. Kim, J.Y. Lee, J.Y. Yun, J.Y. Kim, S.H. Paek, B.S. Jeon (Seoul, Korea)

868

Suicide ideation and behaviors after deep brain stimulation for Parkinson's disease: Results from a randomized, controlled trial

D. Weintraub, J. Duda, K. Carlson, P. Luo, O. Sagher, F. Weaver (Philadelphia, PA, USA)

841

Minor hallucinations are a frequent and even pre-motor symptom in early untreated Parkinson's disease

J. Pagonabarraga, S. Martinez-Horta, R. Fernández de Bobadilla, C. Villa, R. Ribosa, C. García, B. Pascual-Sedano, A. Gironell, J. Kulisevsky (Barcelona, Spain)

831

Thinning of retina from nasal part associates with visual hallucinatory experience in patients with Parkinson's disease wtih intact cognition

J.Y. Lee, T.W. Kim, H.J. Kim, B.S. Jeon (Seoul, Korea)

GUIDED POSTER TOUR 13 - Liffey Hall 1 Thursday, June 21, 2012 12:00 - 13:30

Dystonia

1102

Clinical characteristics of dystonia in patients with Wilson's disease; the frequency of extensor truncal dystonia

A.S. Shalash, T.Y. AbdelGhaffar, S.M. Elsayed (Cairo, Egypt)

1081

Neuropathology of primary cervical dystonia

C.N. Prudente, J. Xiao, C.A. Pardo-Villamizar, M.S. LeDoux, H.A. Jinnah (Atlanta, GA, USA)

1029

Generation of a novel rodent model of DYT1 dystonia

K. Grundmann, T. Ott, N. Gloeckle, M. Walter, M. Bonin, H.P. Nguyen, T.K. Hauser, B. Fehrenbacher, M. Schaller, B. Nuscher, C. Haass, G. Martella, A. Pisani, Z. Yue, O. Riess (Tuebingen, Germany)

1023

A rat knockin model of early onset DYT1 generalized dystonia displays abnormal hindlimb gait

C.T. Frenz, M. Singh, P. Shashidharan (New York, NY, USA)

1090

Tremor dominant cervical dystonia is likely to be familial: Clinical characteristics of a large cohort

I. Rubio Agustí, I. Pareés, M. Kojovic, M.J. Edwards, K.P. Bhatia (London, United Kingdom)

1044

Penetrance of abnormal temporal discrimination thresholds in unaffected first-degree relatives of adult onset primary torsion dystonia patients

O. Kimmich, A. Molloy, D. Bradley, R. Whelan, S. O'Riordan, R.B. Reilly, S. Hutchinson, M. Hutchinson (Dublin, Ireland)

1121

Identification of the genetic cause in the Australian family with spasmodic dysphonia (DYT4)

S. Winkler, A. Ramirez, J. Nahrstaedt, C. Hemmelmann, J. Groen, J. Hagenah, M.A.J. de Koning-Tijssen, A. Ziegler, R.A. Wilcox, C. Klein, K. Lohmann (Lübeck, Germany)

1031

Cerebellar modulation of human associative plasticity

M. Hamada, N. Murase, A. Sadnicka, J.M. Galea, M.J. Edwards, J.C. Rothwell (London, United Kingdom)

1100

Myofibrillar disorganization characterizes myopathy of camptocormia in Parkinson's disease

A. Wrede, N.G. Margraf, H.H. Goebel, G. Deuschl, W.J. Schulz-Schaeffer (Göttingen, Germany)

1036

Immunotherapy-responsive faciobrachial dystonic seizures (FBDS) associated with LGI1-antibodies: A differential diagnosis in movement disorder practice

S.R. Irani, S.A. Schneider, R. Pettingill, S.J.M. Smith, M.R. Johnson, A. Vincent (Oxford, United Kingdom)

GUIDED POSTER TOUR 14 - Liffey Hall 2 Thursday, June 21, 2012 12:00 - 13:30

Parkinsonisms (parkinson plus and secondary)

1197

Abnormalities of voice quality in progressive supranuclear palsy (PSP)

S. Skodda, W. Grönheit, U. Schlegel (Bochum, Germany)

1214

Atypical parkinsonian syndromes and fracture risk – Are patients adequately managed?

A.J. Yarnall, G.W. Duncan, T.K. Khoo, D.J. Burn (Newcastle-upon-Tyne, United Kingdom)

1138

Pure parkinsonism in chorea-acanthocytosis: Postmortem evidence for a striato-pallidal process without involvement of the substantia nigra pars compacta

B.S. Connolly, L.N. Hazrati, A.E. Lang (Toronto, ON, Canada)

1166

Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease

H. Ling, L. Massey, A. Lees, P. Brown, B. Day (London, United Kingdom)

1193

Update on ephedrone induced parkinsonism with dystonia: Four year follow up

Y. Sanotsky, M. Selikhova, L. Fedorishin, Y. Matvienko, I. Komnatska, H. Grey, E. Tripoliti, A.J. Lees (London, United Kingdom)

1201

Impaired primary motor cortex LTP/LTD-like plasticity in multiple system atrophy

A. Suppa, L. Marsili, F. Di Stasio, A. Latorre, A. Khandker Parvez, C. Colosimo, G. Fabbrini, A. Berardelli (Rome, Italy)

1165

Clinicopathological study of progressive supranuclear palsy presenting with corticobasal syndrome

H. Ling, R. de Silva, R. Courtney, L. Massey, N. Bajaj, J. Lowe, J. Holton, A. Lees, T. Revesz (London, United Kingdom)

1186

Accuracy of the NINDS-SPSP and the NNIPPS diagnostic criteria for the clinical diagnosis of progressive supranuclear palsy

G. Respondek, S. Roeber, C. Gaig, C. Troakes, J. Van Swieten, W.H. Oertel, G.U. Hoeglinger (Munich, Germany)

1160

Characterization of movement disorder phenomenology in genetically or pathologically proven frontotemporal lobar degeneration: A systematic review of the literature

B.B. Shah, M. Masellis, D. Harmic, D. Fisman, G. Kleiner-Fisman (Toronto, ON, Canada)

1200

Parkinsonism in hereditary diffuse leukoencephalopathy with axonal spheroids due to CSF1R gene mutation

C. Sundal, J. Van Gerpen, A. Nicholson, M. Baker, C. Wider, E. Shuster, J. Aasly, S. Spina, B. Ghetti, S. Roeber, A. Tselis, R. Swerdlow, B. Miller, S. Fujioka, R. Uitti, O. Ross, R. Rademakers, K. Josephs, D. Dickson, Z. Wszolek (Jacksonville, FL, USA)

GUIDED POSTER TOUR 15 - Wicklow Hall 1 Thursday, June 21, 2012 12:00 - 13:30

Tremor

1233

Modulation of orthostatic tremor during gait

C. Blahak, M.E. Wolf, H. Bäzner, H.H. Capelle, J.K. Krauss, M.G. Hennerici (Mannheim, Germany)

1243

Essential tremor and tremor associated with dystonia are two distinct clinical entities by tactile and proprioceptive temporal dicrimination tests

A. Fasano, T. Bovi, A. Di Matteo, A. Fiaschi, F. Bove, M. Fiorio, A. Berardelli, M. Tinazzi (Verona, Italy)

1239

Long term history of orthostatic tremor: A review of 50 patients

F. Di Biasio, S.L. Pullman, J.C. Cortés, Q.P. Yu, C. Hess, S. Fahn (Rome, Italy)

1263

Tremor clusters in the VIM associated with essential tremor and Parkinson's disease

D.J. Pedrosa, C. Reck, M. Maarouf, L. Wojtecki, A.M. Pauls, V. Sturm, A. Schnitzler, G.R. Fink, L. Timmermann (Cologne, Germany)

1266

Mild cognitive impairment in essential tremor

M. Petrova, M. Raycheva, Y. Zhelev, O. Grigorova, L. Traykov (Sofia, Bulgaria)

54

Survey of cognitive screening in Parkinson's disease across UK centres

S. Hanumantha Reddy, B. Elliott, D. MacMahon, Delegates at the 16th BGS Parkinson's Academy (London, United Kingdom)

1235

Identifying different pathological tremor characteristics with a smart phone

B. Carignan, J.F. Daneault, C.E. Codere, A.F. Sadikot, C. Duval (Terrebonne, QC, Canada)

1273

Clinical features of parkinsonism with tremor associated with scans without evidence of dopaminergic deficit (SWEDDs)

A. Sacko, V. Moullart, C. Duru, P.E. Merle, O. Godefroy, P. Krystkowiak (Bobigny, France)

1267

Corticomuscular coherence in asymptomatic first degree relatives of patients with essential tremor

J. Raethjen, A. Kostka, M. Muthuraman, M. Nahrwohld, D. Lorenz, G. Deuschl (Kiel, Germany)

1274

Diagnosis of psychogenic tremor using a smartphone

T.A. Saifee, P. Kassavetis, L. Drougkas, G. Roussos, I. Pareés, P. Schwingenschuh, P. Katschnig, K.P. Bhatia, J.C. Rothwell, M.J. Edwards (London, United Kingdom)

GUIDED POSTER TOUR 16 - Wicklow Hall 2 Thursday, June 21, 2012 12:00 - 13:30

Surgical therapy of movement disorders other than Parkinson's disease

959

Factors predicting improvement in essential head tremor following deep brain stimulation

M. Moscovich, T. Morishita, C. Favilla, Z. Peng, K. Foote, M. Okun (Gainesville, FL, USA)

946

Evaluation of the therapeutic profit of nucleus accumbens core on the impulsivity/compulsivity balance in rats

S. Ansquer, A. Belin-Rauscent, E. Dugast, M. Francheteau, J.L. Houeto, D. Belin (Poitiers, France)

958

Cervical dystonia improves with high frequency but not with low frequency pallidal stimulation

E. Moro, B.M. Pascual-Sedano, B. Shah, Y.Y. Poon, M. Fallis, A.M. Lozano, M. Hodaie, P. Hagen, C. Brücke, G.H. Schneider, A. Kühn (Toronto, ON, Canada)

981

Electrophysiology of the anteromedial GPi in Tourette syndrome: A case study

S.E. Zauber, S. Ahn, R.M. Worth, L. Rubchinsky (Indianapolis, IN, USA)

962

Prospective assessment of low- versus high-frequency bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in patients with primary dystonia

J.L. Ostrem, G.A. Glass, L.C. Markun, C.A. Racine, M.M. Volz, S.L. Heath, P.A. Starr (San Francisco, CA, USA)

949

Treatment of tremor in multiple sclerosis by thalamic deep brain stimulation

F. Hofschulte, S. Paschen, J. Raethjen, H.M. Mehdorn, J. Volkmann, G. Deuschl (Kiel, Germany)

957

Successful GPi-Deep brain stimulation in Tourette syndrome (GTS) – Much more than improvement of tics

J.H. Mehrkens, K. Boetzel, B. Leitner, B. Feddersen, N. Müller, S. Dehning (Munich, Germany)

980

Effect of bilateral pallidal deep brain stimulation in primary dystonia

F. Yokochi, M. Taniguchi, R. Okiyama, S. Kumada (Tokyo, Japan)

969

Long-term follow-up in patients with deep brain stimulation for cervical dystonia

M.W.M. Schüpbach, H. You, I.U. Isaias, T. Loennfors- Weitzel, F. Vingerhoets, J.K. Krauss, J.M. Burgunder, E. Taub, A. Stibal, A. Kaelin-Lang (Bern, Switzerland)

951

A double-blind, randomized, controlled, crossover trial of bilateral deep brain stimulation to the globus pallidus internus in severe Tourette syndrome

Z. Kefalopoulou, L. Zrinzo, M. Beigi, M. Hariz, M. Jahanshahi, P. Limousin, E. Joyce, T. Foltynie (London, United Kingdom)

Ancillary